Mert Tokatlı, Neslihan Nisa Gecici, Meral Ilgaz Ergin, Gulay Mart, Elifcan Aladağ Karakulak, U. Karakulak, I. Haznedaroglu
Ponatinib is a third-generation tyrosine kinase inhibitor with potent efficacy in the treatment of acute and chronic leukemia. Despite having an effective and sustained activity in all BCR-ABL1 mutations, it may cause cardiovascular adverse effects. Here we report a 56-year-old male patient with Chronic myeloid leukemia and no prior cardiac disorder who developed acute heart failure under ponatinib treatment. Guideline-recommended medical treatment for heart failure was initiated. Coronary angiography to exclude ischemic heart disease revealed no coronary stenosis. Cardiac magnetic resonance imaging showed findings consistent with non-ischemic dilated cardiomyopathy. After interruption of ponatinib treatment, cardiac evaluation showed improvement in left ventricular ejection fraction. Patients on Ponatinib therapy should be closely monitored for signs and symptoms of heart failure.
{"title":"Ponatinib-induced dilated cardiomyopathy: a case report","authors":"Mert Tokatlı, Neslihan Nisa Gecici, Meral Ilgaz Ergin, Gulay Mart, Elifcan Aladağ Karakulak, U. Karakulak, I. Haznedaroglu","doi":"10.51271/jchor-0023","DOIUrl":"https://doi.org/10.51271/jchor-0023","url":null,"abstract":"Ponatinib is a third-generation tyrosine kinase inhibitor with potent efficacy in the treatment of acute and chronic leukemia. Despite having an effective and sustained activity in all BCR-ABL1 mutations, it may cause cardiovascular adverse effects. Here we report a 56-year-old male patient with Chronic myeloid leukemia and no prior cardiac disorder who developed acute heart failure under ponatinib treatment. Guideline-recommended medical treatment for heart failure was initiated. Coronary angiography to exclude ischemic heart disease revealed no coronary stenosis. Cardiac magnetic resonance imaging showed findings consistent with non-ischemic dilated cardiomyopathy. After interruption of ponatinib treatment, cardiac evaluation showed improvement in left ventricular ejection fraction. Patients on Ponatinib therapy should be closely monitored for signs and symptoms of heart failure.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"118 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139200299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ali Doğan, Ömer Ekinci, Narin Yıldırım Doğan, Taner Kıvanç, Sinan Demircioğlu, C. Demir, Cihan Ural, Ramazan Esen, Ahmet Karakarçayıldız, Yasin Mamiş
Aims: The aim of this study was to evaluate the rate of hepatitis B virus reactivation (HBVr) in hematology patients receiving immunosuppressive therapy in our center and the clinical characteristics of patients with HBVr. We will also investigate the importance of effective prevention of this potentially life-threatening event and management of hepatitis B virus (HBV) prophylaxis. Methods: In this study, hepatitis B prophylaxis and its effects on patients over 18 years of age receiving immunosuppressive therapy in the hematology clinic were analyzed. 122 patients were included in the study. The HBV markers of the patients were determined by the chemiluminescence method. In the study, HbsAg(+) and isolated antiHbc IgG-positive patients received prophylactic antiviral treatment. The differential diagnosis of HBV reactivation and the criteria determined to define HBV reactivation were performed. Clinical characteristics and descriptive information of patients receiving HBV prophylaxis were analyzed using SPSS 25.0. Results: The median age of 122 patients (59.8% male) was 58 years. It was determined that five HbsAg-positive patients had no prior follow-up and did not receive antiviral treatment. 117 patients had isolated anti-HBc IgG positivity. The median duration of prophylaxis was 15 (9- 21.25) months, and the total follow-up period was 19.5 (11.75- 30.25) months. 81.1% of the patients received regular HBV prophylaxis treatment; 59% of them received entecavir, and the rest received tenofovir disoproxil. Bone marrow transplantation was performed in 25 patients. HBV reactivation was detected in only 4 patients (3.3%); one of these patients had received allogeneic and one autologous bone marrow transplantation; and three patients had received chemoimmunotherapy including Rituximab. The diagnoses of the patients with HBVr were acute myeloid leukemia, lymphoma, and chronic lymphocytic leukemia. During the follow-up period, 29 patients (23.8%) died due to their primary disease, but there were no deaths due to HBV reactivation. Conclusion: The data obtained in this study show that effective hepatitis B prophylaxis treatment is successful in preventing HBV reactivation in hematology patients. HBVr was observed in four patients who did not take HBV prophylaxis medication regularly.
{"title":"Evaluation of the frequency of hepatitis b virus reactivation and the importance of hepatitis b prophylaxis in hematology patients receiving immunosuppressive therapy: a single-center study","authors":"Ali Doğan, Ömer Ekinci, Narin Yıldırım Doğan, Taner Kıvanç, Sinan Demircioğlu, C. Demir, Cihan Ural, Ramazan Esen, Ahmet Karakarçayıldız, Yasin Mamiş","doi":"10.51271/jchor-0019","DOIUrl":"https://doi.org/10.51271/jchor-0019","url":null,"abstract":"Aims: The aim of this study was to evaluate the rate of hepatitis B virus reactivation (HBVr) in hematology patients receiving immunosuppressive therapy in our center and the clinical characteristics of patients with HBVr. We will also investigate the importance of effective prevention of this potentially life-threatening event and management of hepatitis B virus (HBV) prophylaxis. Methods: In this study, hepatitis B prophylaxis and its effects on patients over 18 years of age receiving immunosuppressive therapy in the hematology clinic were analyzed. 122 patients were included in the study. The HBV markers of the patients were determined by the chemiluminescence method. In the study, HbsAg(+) and isolated antiHbc IgG-positive patients received prophylactic antiviral treatment. The differential diagnosis of HBV reactivation and the criteria determined to define HBV reactivation were performed. Clinical characteristics and descriptive information of patients receiving HBV prophylaxis were analyzed using SPSS 25.0. Results: The median age of 122 patients (59.8% male) was 58 years. It was determined that five HbsAg-positive patients had no prior follow-up and did not receive antiviral treatment. 117 patients had isolated anti-HBc IgG positivity. The median duration of prophylaxis was 15 (9- 21.25) months, and the total follow-up period was 19.5 (11.75- 30.25) months. 81.1% of the patients received regular HBV prophylaxis treatment; 59% of them received entecavir, and the rest received tenofovir disoproxil. Bone marrow transplantation was performed in 25 patients. HBV reactivation was detected in only 4 patients (3.3%); one of these patients had received allogeneic and one autologous bone marrow transplantation; and three patients had received chemoimmunotherapy including Rituximab. The diagnoses of the patients with HBVr were acute myeloid leukemia, lymphoma, and chronic lymphocytic leukemia. During the follow-up period, 29 patients (23.8%) died due to their primary disease, but there were no deaths due to HBV reactivation. Conclusion: The data obtained in this study show that effective hepatitis B prophylaxis treatment is successful in preventing HBV reactivation in hematology patients. HBVr was observed in four patients who did not take HBV prophylaxis medication regularly.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"255 7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139202400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Z. Erdin, Özlem Gül, Bilal Ergül, Rıdvan Erdin, Harın Erdal, Üçler Kısa, Dilek Oğuz
Aims: Liver cancer is the second most common cause of cancer death, and hepatocellular carcinoma (HCC) is the most common hepatic primary tumor. Hepatocellular carcinoma develops based on inflammation in the cirrhotic liver. The aim of our study was to determine the relationship between the decrease in Resolvin D1, the lipid mediator involved in the resolution, and hepatocarcinogenesis. Methods: Thirty patients with HCC, thirty patients with cirrhosis, and thirty healthy subjects followed in our clinic between March 2018 and June 2019 were included in the study. Routine laboratory test results of the patients were recorded from the institutional database. Resolvin D1 and other parameters of the study groups were compared. Results: The Resolvin D1 levels were found to be significantly different from each other group, with the ranking as follows: the HCC group (1.71 ± 1.46 ng/ml)< the cirrhotic group (3.63 ± 2.92 ng/ml)< the healthy control group (6.24 ± 3.18 ng/ml). Moreover, Resolvin D1 levels were negatively correlated with ?-fetoprotein (AFP) level and tumor stage. Conclusion: Reduced lipid mediators that aid in the resolution process cause an increase in pro-inflammatory cytokines involved in the development of hepatocellular carcinoma. A decrease in Resolvin D1 may serve as a biomarker contributing to the diagnosis of progression to HCC in cirrhotic patients by triggering chronic inflammation and hepatocarcinogenesis.
{"title":"The relationship between hepatocellular carcinoma and Resolvin D1","authors":"Z. Erdin, Özlem Gül, Bilal Ergül, Rıdvan Erdin, Harın Erdal, Üçler Kısa, Dilek Oğuz","doi":"10.51271/jchor-0021","DOIUrl":"https://doi.org/10.51271/jchor-0021","url":null,"abstract":"Aims: Liver cancer is the second most common cause of cancer death, and hepatocellular carcinoma (HCC) is the most common hepatic primary tumor. Hepatocellular carcinoma develops based on inflammation in the cirrhotic liver. The aim of our study was to determine the relationship between the decrease in Resolvin D1, the lipid mediator involved in the resolution, and hepatocarcinogenesis. Methods: Thirty patients with HCC, thirty patients with cirrhosis, and thirty healthy subjects followed in our clinic between March 2018 and June 2019 were included in the study. Routine laboratory test results of the patients were recorded from the institutional database. Resolvin D1 and other parameters of the study groups were compared. Results: The Resolvin D1 levels were found to be significantly different from each other group, with the ranking as follows: the HCC group (1.71 ± 1.46 ng/ml)< the cirrhotic group (3.63 ± 2.92 ng/ml)< the healthy control group (6.24 ± 3.18 ng/ml). Moreover, Resolvin D1 levels were negatively correlated with ?-fetoprotein (AFP) level and tumor stage. Conclusion: Reduced lipid mediators that aid in the resolution process cause an increase in pro-inflammatory cytokines involved in the development of hepatocellular carcinoma. A decrease in Resolvin D1 may serve as a biomarker contributing to the diagnosis of progression to HCC in cirrhotic patients by triggering chronic inflammation and hepatocarcinogenesis.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139199380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Autoimmune Hemolytic Anemia (AIHA) is hemolytic anemia characterized by auto-antibodies directed to erythrocytes. It is commonly induced by hematological neoplasms such as malignant lymphoma; however urological cancers are rarely seen in this area. We present a case of clear cell renal carcinoma that responded to right partial nephrectomy, presenting with Coombs-positive warm AIHA. A 34-year-old male patient presented with fatigue lasting for 1 week, and yellowing of the eyes and body. His hemoglobin level was 6.8 g/dL, indirect bilirubin was 9.3 mg/dL, lactate dehydrogenase (LDH) 1031 U/L and both direct and indirect Coombs tests were positive. In abdominal computed tomography, there was a 6 cm diameter mass lesion of heterogeneous density in the middle part of the right kidney. Corticosteroid treatment was started and then partial nephrectomy was performed. After surgical resection, the hemoglobin level gradually returned to normal. We detected warm AIHA associated with clear cell renal cancer. We are reporting a clear cell renal cancer that responded to corticosteroid and partial nephrectomy, who came to the hematology clinic with severe AIHA. Clear cell renal cancer should be considered in the differential diagnosis for warm AIHA, and nephrectomy might offer a treatment option for renal cell carcinoma associated AIHA.
{"title":"Autoimmune hemolytic anemia associated with clear cell renal carcinoma: A case report","authors":"Serkan Güven, N. Ak","doi":"10.51271/jchor-0022","DOIUrl":"https://doi.org/10.51271/jchor-0022","url":null,"abstract":"Autoimmune Hemolytic Anemia (AIHA) is hemolytic anemia characterized by auto-antibodies directed to erythrocytes. It is commonly induced by hematological neoplasms such as malignant lymphoma; however urological cancers are rarely seen in this area. We present a case of clear cell renal carcinoma that responded to right partial nephrectomy, presenting with Coombs-positive warm AIHA. A 34-year-old male patient presented with fatigue lasting for 1 week, and yellowing of the eyes and body. His hemoglobin level was 6.8 g/dL, indirect bilirubin was 9.3 mg/dL, lactate dehydrogenase (LDH) 1031 U/L and both direct and indirect Coombs tests were positive. In abdominal computed tomography, there was a 6 cm diameter mass lesion of heterogeneous density in the middle part of the right kidney. Corticosteroid treatment was started and then partial nephrectomy was performed. After surgical resection, the hemoglobin level gradually returned to normal. We detected warm AIHA associated with clear cell renal cancer. We are reporting a clear cell renal cancer that responded to corticosteroid and partial nephrectomy, who came to the hematology clinic with severe AIHA. Clear cell renal cancer should be considered in the differential diagnosis for warm AIHA, and nephrectomy might offer a treatment option for renal cell carcinoma associated AIHA.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139205773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Serhat Çelik, M. Keklik, Olgun Kontaş, Mehmet Yavuz Köker, L. Kaynar
Acute basophilic leukemia is an extremely rare form of acute myeloid leukemia and diagnosis is based on morphological, cytochemical and ultrastructural analyses of basophils and blastic cells. It is usually characterized by a very rapid clinical course, symptoms of hyperhistaminemia and resistance to therapy. A 73 year-old male presented with itching, thrombocytopenia and leukocytosis. There was no hepatosplenomegaly. In the flow cytometry evaluation of peripheral blood, CD123 positive myeloid blasts were detected at the rate of 60%. Also, CD13 and CD33 were positive, while CD34, CD117, HLA DR and myeloperoxidase (MPO) were negative. These findings were considered as consistent with ABL. Following, the diagnosis of ABL was confirmed by bone marrow evaluation including cytomorphological and immunohistochemical studies. On the other hand, cytogenetical analyses of bone marrow showed the presence of the Philadelphia chromosome.The patient received one cycle of a chemotherapy regimen including cytarabine and idarubicin with imatinib support, but he died on the 10th hospital day. Considering that ABL behaves in a very malignant fashion, and a more aggressive treatment approach is necessary for patients with this specific subtype of AML.
{"title":"A rare case of acute basophilic leukemia","authors":"Serhat Çelik, M. Keklik, Olgun Kontaş, Mehmet Yavuz Köker, L. Kaynar","doi":"10.51271/jchor-0016","DOIUrl":"https://doi.org/10.51271/jchor-0016","url":null,"abstract":"Acute basophilic leukemia is an extremely rare form of acute myeloid leukemia and diagnosis is based on morphological, cytochemical and ultrastructural analyses of basophils and blastic cells. It is usually characterized by a very rapid clinical course, symptoms of hyperhistaminemia and resistance to therapy. A 73 year-old male presented with itching, thrombocytopenia and leukocytosis. There was no hepatosplenomegaly. In the flow cytometry evaluation of peripheral blood, CD123 positive myeloid blasts were detected at the rate of 60%. Also, CD13 and CD33 were positive, while CD34, CD117, HLA DR and myeloperoxidase (MPO) were negative. These findings were considered as consistent with ABL. Following, the diagnosis of ABL was confirmed by bone marrow evaluation including cytomorphological and immunohistochemical studies. On the other hand, cytogenetical analyses of bone marrow showed the presence of the Philadelphia chromosome.The patient received one cycle of a chemotherapy regimen including cytarabine and idarubicin with imatinib support, but he died on the 10th hospital day. Considering that ABL behaves in a very malignant fashion, and a more aggressive treatment approach is necessary for patients with this specific subtype of AML.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127983888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amyloidosis is a rare and fatal disease that occurs with the accumulation of amyloid protein in the organs. The most common presentations are nephrotic syndrome, cardiomyopathy, and unexplained hepatomegaly. We present a case of small cell lung cancer as a result of mediastinoscopic biopsy in a patient who presented with a lung mass and 18-FDG uptake on PET/CT, and amyloidosis was found in the bronchoscopic biopsy result.
{"title":"Association of amyloidosis and lung cancer; a case of small cell lung cancer masked by amyloidosis with 18-fdg uptake","authors":"Cebrail Azar, Ş. Azar, Tülin Öztürk, Tayfun Kermenli, Hidayet Kayançiçek, Tamer İmamoğlu","doi":"10.51271/jchor-0017","DOIUrl":"https://doi.org/10.51271/jchor-0017","url":null,"abstract":"Amyloidosis is a rare and fatal disease that occurs with the accumulation of amyloid protein in the organs. The most common presentations are nephrotic syndrome, cardiomyopathy, and unexplained hepatomegaly. We present a case of small cell lung cancer as a result of mediastinoscopic biopsy in a patient who presented with a lung mass and 18-FDG uptake on PET/CT, and amyloidosis was found in the bronchoscopic biopsy result.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116646844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cold agglutinins are antibodies that recognize antigens on erythrocytes at temperatures below normal body temperature. Antibodies are of IgM nature and bind to “I” or “i” antigens on red blood cells, causing agglutination in red blood cells. This situation results in anemia by creating extravascular hemolysis. If there is no underlying disease, it is called primary or idiopathic cold agglutinin disease (CAD), and if there is, it is called secondary cold agglutinin syndrome (CAS). Primary CAD is an extremely rare disease, with an incidence and prevalence of 1 per million and 16 per million, respectively. It is seen twice more in women than in men, and the median age of diagnosis is 67 (between 30-92 years). The etiology of CAS includes infections, autoimmune and lymphoproliferative diseases. There are cold-related symptoms and symptoms of anemia in the clinic. In treatment, it is necessary to avoid cold in order to reduce cold-induced symptoms and hemolysis. Currently, the most effective treatment for reducing antibody production is rituximab. It can be given alone or in combination with bendamustine, interferon alfa, fludarabine and prednisolone. bortezomib is used when rituximab is ineffective or contraindicated. Plasmapheresis or intravenous immunoglobulin can be given when there is critical hemolysis or when the effectiveness of immunosuppressive therapy may start late. Treatment in CAS is the treatment of the underlying disease.
{"title":"Cold autoimmune hemolytic anemia","authors":"Serhat Çelik, Ali Ünal","doi":"10.51271/jchor-0015","DOIUrl":"https://doi.org/10.51271/jchor-0015","url":null,"abstract":"Cold agglutinins are antibodies that recognize antigens on erythrocytes at temperatures below normal body temperature.\u0000Antibodies are of IgM nature and bind to “I” or “i” antigens on red blood cells, causing agglutination in red blood cells.\u0000This situation results in anemia by creating extravascular hemolysis. If there is no underlying disease, it is called primary\u0000or idiopathic cold agglutinin disease (CAD), and if there is, it is called secondary cold agglutinin syndrome (CAS). Primary\u0000CAD is an extremely rare disease, with an incidence and prevalence of 1 per million and 16 per million, respectively. It is seen\u0000twice more in women than in men, and the median age of diagnosis is 67 (between 30-92 years). The etiology of CAS includes infections, autoimmune and lymphoproliferative diseases. There are cold-related symptoms and symptoms of anemia in the clinic. In treatment, it is necessary to avoid cold in order to reduce cold-induced symptoms and hemolysis. Currently, the most effective treatment for reducing antibody production is rituximab. It can be given alone or in combination with bendamustine, interferon alfa, fludarabine and prednisolone. bortezomib is used when rituximab is ineffective or contraindicated. Plasmapheresis or intravenous immunoglobulin can be given when there is critical hemolysis or when the effectiveness of immunosuppressive therapy may start late. Treatment in CAS is the treatment of the underlying disease.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120958801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aims: The activation of the Wnt/ ß-catenin signaling pathway has been demonstrated to play a crucial role in the development of myeloid neoplasms. In addition to CD34, which has been used until now in the diagnosis and staging of clonal hematopoietic diseases, Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN), CD117, which has found its place in hematopoietic diseases, also provides significant benefits in these respects. In this study, we evaluated the immunohistochemical presence and utility of ß-catenin in blasts relative to other markers, as the inhibition of ß-catenin activity may be an attractive therapeutic approach Methods: By retrospectively analyzing bone marrow samples with ß-catenin immune marker, we determined the staining rates, intensities, and patterns of 30 MDS, 29 MPN cases and 30 normal bone marrow controls, in comparison to the efficacy of the the well-known CD34 and CD117. We statistically interpreted the correlation between them. Results: Based on the findings, ß-catenin, which has recently been used in hematopoietic diseases and is said to have a high efficacy in acute myeloid leukemia (AML) cases, was not immunohistochemically detectable in our study. As expected, CD34 and CD117 immun markers exhibited significant blast staining. MPN cases were more prone to staining with CD117. Conclusion: CD34 continues to be the most reliable marker for identifying blasts for diagnosing and grading bone marrow neoplasms while CD117 may have a supportive role in this process. Further investigation is required to ascertain the true effectiveness of ß-catenin, a molecule that has demonstrated encouraging potential in the context of AML.
{"title":"ß-catenin expression in myelodysplastic syndromes and myeloproliferative neoplasms in bone marrow, in relation to CD34 and CD117 status","authors":"I. Bariş, Hüseyin Büyükbayram","doi":"10.51271/jchor-0013","DOIUrl":"https://doi.org/10.51271/jchor-0013","url":null,"abstract":"Aims: The activation of the Wnt/ ß-catenin signaling pathway has been demonstrated to play a crucial role in the development of myeloid neoplasms. In addition to CD34, which has been used until now in the diagnosis and staging of clonal hematopoietic diseases, Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN), CD117, which has found its place in hematopoietic diseases, also provides significant benefits in these respects. In this study, we evaluated the immunohistochemical presence and utility of ß-catenin in blasts relative to other markers, as the inhibition of ß-catenin activity may be an attractive therapeutic approach \u0000Methods: By retrospectively analyzing bone marrow samples with ß-catenin immune marker, we determined the staining\u0000rates, intensities, and patterns of 30 MDS, 29 MPN cases and 30 normal bone marrow controls, in comparison to the efficacy of the the well-known CD34 and CD117. We statistically interpreted the correlation between them.\u0000Results: Based on the findings, ß-catenin, which has recently been used in hematopoietic diseases and is said to have a high\u0000efficacy in acute myeloid leukemia (AML) cases, was not immunohistochemically detectable in our study. As expected, CD34\u0000and CD117 immun markers exhibited significant blast staining. MPN cases were more prone to staining with CD117.\u0000Conclusion: CD34 continues to be the most reliable marker for identifying blasts for diagnosing and grading bone marrow\u0000neoplasms while CD117 may have a supportive role in this process. Further investigation is required to ascertain the true\u0000effectiveness of ß-catenin, a molecule that has demonstrated encouraging potential in the context of AML.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129864688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aims: Pancreatic cancer attracts attention with its increasing frequency among gastrointestinal cancers. It has the worst prognosis of all cancer types. In this study, we aimed to retrospectively evaluate the clinical features and treatment results of our patients with advanced pancreatic cancer. Methods: In this study, 131 patients diagnosed with advanced pancreatic cancer and admitted to the Ankara Numune Training and Research Hospital Medical Oncology Polyclinic between November 2002 and January 2014 were retrospectively analyzed. Demographic characteristics of the patients, smoking, family history, basal CEA and basal CA 19-9 levels, treatment modalities, metastasis sites, progression-free survival, and overall survival times were evaluated. Results: The study population consisted of 131 patients, including 94 males and 37 females. Twenty of the patients were in the locally advanced stage, and 111 were in the metastatic stage. The median age of the patients was 60 years. 53.4% of the patients were smokers, and the median amount of smoking was 30 packs/year. Adenocancer was the most common histopathological subtype. The median basal CEA and Ca 19-9 levels were high at the time of diagnosis. Neoadjuvant chemotherapy was given to all locally advanced patients. The most commonly used chemotherapy regimens were single-agent gemcitabine and gemcitabine-cisplatin combination therapies. While 10 of the locally advanced patients received local treatment (chemotherapy or surgery) after neoadjuvant chemotherapy, the remaining 10 patients could not receive local treatment. The median overall and progression-free survival times were found to be significantly longer in patients with locally advanced disease who received local treatment after neoadjuvant chemotherapy [(18 months vs. 6.5 months; p=0.008), (11.3 months vs. 6.4 months; p=0.05)]. The most common site of metastasis in our patients with metastatic pancreatic cancer was the liver (80%). Cisplatin-gemcitabine was preferred as a KT regimen in 63.4% of metastatic cases. The median overall survival time of the patients in the metastatic stage was 8.1 months, and the median progression-free survival time was 5.7 months. The median progression-free survival of all patients included in the study was 6.2 months, while the median overall survival was 8.8 months. Conclusion: The median overall survival of patients with locally advanced pancreatic cancer was significantly longer compared to metastatic patients (18 months vs. 8.1 months; p=0.028). Progression-free survival and overall survival of patients with locally advanced disease who received or did not receive local treatment after neoadjuvant chemotherapy were found to be significantly longer in patients who received local treatment. (11.3 months vs. 6.4 months; p=0.05) (18 months vs. 6.5 months; p=0.008). Response rates of patients with metastatic pancreatic cancer; It was 49% in the gemcitabine-cisplatin combination arm and 30% in the single-agent
{"title":"Retrospective evaluation of our patients diagnosed with advanced pancreatic cancer","authors":"Z. Güven, Selma Özkan Karaahmetoğlu, Mutlu Doğan","doi":"10.51271/jchor-0012","DOIUrl":"https://doi.org/10.51271/jchor-0012","url":null,"abstract":"Aims: Pancreatic cancer attracts attention with its increasing frequency among gastrointestinal cancers. It has the worst prognosis of all cancer types. In this study, we aimed to retrospectively evaluate the clinical features and treatment results of our patients with advanced pancreatic cancer. \u0000Methods: In this study, 131 patients diagnosed with advanced pancreatic cancer and admitted to the Ankara Numune Training and Research Hospital Medical Oncology Polyclinic between November 2002 and January 2014 were retrospectively analyzed. Demographic characteristics of the patients, smoking, family history, basal CEA and basal CA 19-9 levels, treatment modalities, metastasis sites, progression-free survival, and overall survival times were evaluated. \u0000Results: The study population consisted of 131 patients, including 94 males and 37 females. Twenty of the patients were in the locally advanced stage, and 111 were in the metastatic stage. The median age of the patients was 60 years. 53.4% of the patients were smokers, and the median amount of smoking was 30 packs/year. Adenocancer was the most common histopathological subtype. The median basal CEA and Ca 19-9 levels were high at the time of diagnosis. Neoadjuvant chemotherapy was given to all locally advanced patients. The most commonly used chemotherapy regimens were single-agent gemcitabine and gemcitabine-cisplatin combination therapies. While 10 of the locally advanced patients received local treatment (chemotherapy or surgery) after neoadjuvant chemotherapy, the remaining 10 patients could not receive local treatment. The median overall and progression-free survival times were found to be significantly longer in patients with locally advanced disease who received local treatment after neoadjuvant chemotherapy [(18 months vs. 6.5 months; p=0.008), (11.3 months vs. 6.4 months; p=0.05)]. The most common site of metastasis in our patients with metastatic pancreatic cancer was the liver (80%). Cisplatin-gemcitabine was preferred as a KT regimen in 63.4% of metastatic cases. The median overall survival time of the patients in the metastatic stage was 8.1 months, and the median progression-free survival time was 5.7 months. The median progression-free survival of all patients included in the study was 6.2 months, while the median overall survival was 8.8 months. \u0000Conclusion: The median overall survival of patients with locally advanced pancreatic cancer was significantly longer compared to metastatic patients (18 months vs. 8.1 months; p=0.028). Progression-free survival and overall survival of patients with locally advanced disease who received or did not receive local treatment after neoadjuvant chemotherapy were found to be significantly longer in patients who received local treatment. (11.3 months vs. 6.4 months; p=0.05) (18 months vs. 6.5 months; p=0.008). Response rates of patients with metastatic pancreatic cancer; It was 49% in the gemcitabine-cisplatin combination arm and 30% in the single-agent","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"84 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121754643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Abedi, Serhat Çelik, Zeynep Dilan Özçelik Yılmaz, Z. Güven, H. Akalın, L. Kaynar
A 48-year-old man was diagnosed Acute myeloid leukemia with FLT3 ITD positive and PML/RAR?- negative. Remission was achieved after induction and consolidation chemotherapy. Allogeneic hematopoietic stem cell transplantation was performed from his full matched sibling donor. He relapsed after 5 years and his bone marrow examination revealed PML/RAR?- positive Acute promyelocytic leukemia. t(15:17) was positive and FLT-3 ITD was negative. Cytogenetic and molecular analysis confirmed donor cell origin. Donor didn’t develop Acute promyelocytic leukemia.
{"title":"Donor cell leukemia after allogeneic hematopoietic stem cell transplantation: a case report","authors":"A. Abedi, Serhat Çelik, Zeynep Dilan Özçelik Yılmaz, Z. Güven, H. Akalın, L. Kaynar","doi":"10.51271/jchor-0011","DOIUrl":"https://doi.org/10.51271/jchor-0011","url":null,"abstract":"A 48-year-old man was diagnosed Acute myeloid leukemia with FLT3 ITD positive and PML/RAR?- negative. Remission was \u0000achieved after induction and consolidation chemotherapy. Allogeneic hematopoietic stem cell transplantation was performed \u0000from his full matched sibling donor. He relapsed after 5 years and his bone marrow examination revealed PML/RAR?-\u0000positive Acute promyelocytic leukemia. t(15:17) was positive and FLT-3 ITD was negative. Cytogenetic and molecular analysis \u0000confirmed donor cell origin. Donor didn’t develop Acute promyelocytic leukemia.","PeriodicalId":171029,"journal":{"name":"Journal of Current Hematology & Oncology Research","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124759143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：